Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study (AAA)
Sponsor: University of Calgary
Terminated
we couldn't recruit enough participants
Other terminated trials from University of Calgary
Other Atrial Fibrillation trials with similar outcome
This PHASE4 trial investigates Atrial Fibrillation and is currently terminated or withdrawn. University of Calgary leads this study, which shows 11 recorded versions since 2022 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE4
-
Jun 2023 — Jun 2024 [monthly]
Recruiting PHASE4
▶ Show 6 earlier versions
-
Mar 2022 — Jun 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE4
-
May 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Calgary
For direct contact, visit the study record on ClinicalTrials.gov .